Background
Sekisui Medical entered the field of blood coagulation analysis reagents in 1979 with “Testzym”, a series of reagents based on the synthetic substrate method. Thanks to its product lineup of Nanopia and Coagpia brands, it now holds the largest share of domestic sales in the field (internal estimation).
Sekisui Medical released the blood coagulation analyzer “Coapresta 2000” in March 2007 and began its medical instrument business where instruments and reagents are combined. Over 200 units of “Coapresta 2000” have been installed mainly in large hospitals such as university hospitals, and it holds the top share for annual domestic deliveries of instruments in its class (internal estimation). Moreover, in April 2009 Sekisui Chemical acquired the US-based American Diagnostica Inc. (ADI), a company that has proven itself in the field of blood coagulation analysis reagents. Joint development of blood coagulation analysis reagents with ADI will create a structure to further enhance Sekisui Medical’s product lineup and is an example of the efforts being made to expand the instruments business in the field of blood coagulation analysis.
With this agreement with Nihon Kohden, Sekisui Medical is going to expand the overseas business of blood coagulation analysis instruments and reagents through Nihon Kohden’s global sales and service network.
Read more here.
Contract Signed For OEM Supply Of Blood Coagulation Analyzers And Dedicated Reagents To The European And South American Markets
SEKISUI MEDICAL CO., LTD. (President: Mutsumi Fukuda, hereinafter Sekisui Medical), a 100% subsidiary of SEKISUI CHEMICAL, CO., LTD. (President: Naofumi Negishi, hereinafter Sekisui Chemical), has signed an OEM agreement to supply blood coagulation analyzers and dedicated reagents to Nihon Kohden Corporation (President & COO: Fumio Suzuki, hereinafter Nihon Kohden) in order to expand its overseas business in the field of blood coagulation analysis. 1.